Patient characteristics, treatment patterns, and clinical outcomes of remdesivir in hospitalized COVID-19 patients with diabetes mellitus on insulin: A large-scale data analysis using a Japanese claims database
Aim: To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV). Methods: We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to seve...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Journal of Clinical Virology Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667038025000158 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: To describe treatment patterns and clinical outcomes in Japanese patients with diabetes mellitus (DM) hospitalized for coronavirus disease-2019 (COVID-19) treated with remdesivir (RDV). Methods: We included data from patients aged ≥ 18 years with DM on insulin, hospitalized for moderate to severe COVID-19, and who received ≥ 1 dose of RDV between October 2021 and September 2022, using a Japanese medical claims database. All-cause mortality, progression to severe COVID-19, and hospital discharge/recovery status were evaluated up to 56 days from the index date defined as RDV initiation. Results: The analysis included 502 patients. The mean (SD) age at index was 74.4 (12.5) years. Median (Q1–Q3) time to RDV initiation was 2.0 (1.0–3.0) days from hospital admission; median treatment duration was 5.0 (3.0–5.0) days. At index date, 36.85 % of patients had moderate I disease (hospitalized without oxygen support), 58.96 % had moderate II disease (non-invasive positive pressure ventilation, low/high-flow oxygen), and 4.18 % had severe disease (ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation). Proportion of patients with all-cause mortality was 11.16 % (95 % CI, 8.54–14.24) and 13.15 % (10.32–16.42) by 28 and 56 days. At 28 days, 12.35 % (9.60–15.55) of patients had disease progression, and 68.13 % (63.85–72.19) had recovery. Conclusion: Most patients were elderly and required oxygen support when initiating RDV. The majority of patients received RDV within 3 days of hospitalization and recovered by 28 days. The study provides insight into outcomes in Japanese COVID-19 patients with DM treated with RDV in inpatient settings. |
|---|---|
| ISSN: | 2667-0380 |